Trials / Unknown
UnknownNCT03766776
Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Anlotinib Hydrochloride Capsules in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Open, Single Arm, Exploratory Clinical Trial.
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, one-arm, exploratory clinical study to observe and evaluate the efficacy and safety of Anlotinib hydrochloride capsules in patients with advanced liver cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Anlotinib capsules: dosage of 12 mg PO qd, 14 days, 7 days, 21 days for a cycle. The dosage was adjusted according to the adverse reactions of patients. |
Timeline
- Start date
- 2018-12-31
- Primary completion
- 2019-12-31
- Completion
- 2020-12-31
- First posted
- 2018-12-06
- Last updated
- 2018-12-11
Source: ClinicalTrials.gov record NCT03766776. Inclusion in this directory is not an endorsement.